S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
S&P 500   3,096.63 (+0.08%)
DOW   27,781.96 (-0.01%)
QQQ   201.43 (-0.08%)
AAPL   262.64 (-0.69%)
FB   193.15 (-0.02%)
MSFT   148.06 (+0.51%)
GOOGL   1,309.15 (+1.00%)
AMZN   1,754.60 (+0.08%)
CGC   15.84 (-14.38%)
NVDA   209.79 (+0.58%)
MU   46.80 (+1.08%)
BABA   182.80 (+0.18%)
GE   11.29 (+0.00%)
TSLA   349.35 (+0.94%)
T   38.95 (-0.54%)
AMD   38.35 (+2.21%)
F   8.79 (-0.23%)
ACB   3.29 (-7.32%)
PRI   130.20 (+1.24%)
NFLX   289.62 (+2.30%)
BAC   32.70 (-0.27%)
GILD   63.81 (+0.76%)
DIS   147.15 (-1.06%)
Log in

Matinas BioPharma News Headlines (NYSEAMERICAN:MTNB)

$0.90
0.00 (0.00 %)
(As of 11/14/2019 04:00 PM ET)
Today's Range
$0.88
Now: $0.90
$1.02
50-Day Range
$0.59
MA: $0.68
$0.75
52-Week Range
$0.50
Now: $0.90
$1.50
Volume2.92 million shs
Average Volume819,785 shs
Market Capitalization$146.18 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Matinas BioPharma (NYSEAMERICAN MTNB) News Headlines

Source:
DateHeadline
Matinas BioPharma (NYSEAMERICAN:MTNB) Announces Quarterly  Earnings ResultsMatinas BioPharma (NYSEAMERICAN:MTNB) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 14 at 5:48 PM
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue EstimatesMatinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 13 at 12:41 PM
Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateMatinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - November 13 at 7:40 AM
Matinas BioPharma (MTNB) to Release Quarterly Earnings on WednesdayMatinas BioPharma (MTNB) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 7 at 10:14 AM
Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019
finance.yahoo.com - November 6 at 8:27 AM
Should You Be Concerned About Matinas BioPharma Holdings, Inc.s (NYSEMKT:MTNB) Historical Volatility?Should You Be Concerned About Matinas BioPharma Holdings, Inc.'s (NYSEMKT:MTNB) Historical Volatility?
finance.yahoo.com - October 28 at 5:15 PM
Should You Be Concerned About Matinas BioPharma Holdings, Inc.'s (NYSEMKT:MTNB) Historical Volatility?Should You Be Concerned About Matinas BioPharma Holdings, Inc.'s (NYSEMKT:MTNB) Historical Volatility?
finance.yahoo.com - October 28 at 5:15 PM
Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal MeningitisMatinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis
finance.yahoo.com - October 14 at 7:47 AM
Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of CryptococcosisMatinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis
finance.yahoo.com - October 7 at 7:55 AM
Matinas BioPharma to Present at the 2019 Cantor Global Healthcare ConferenceMatinas BioPharma to Present at the 2019 Cantor Global Healthcare Conference
finance.yahoo.com - September 27 at 5:09 PM
Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®
finance.yahoo.com - September 25 at 7:02 AM
Matinas BioPharma Holdings (NYSEMKT:MTNB) Is In A Good Position To Deliver On Growth PlansMatinas BioPharma Holdings (NYSEMKT:MTNB) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - September 21 at 3:10 PM
Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment ConferenceMatinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference
finance.yahoo.com - August 28 at 11:26 AM
Edited Transcript of MTNB earnings conference call or presentation 13-Aug-19 12:00pm GMTEdited Transcript of MTNB earnings conference call or presentation 13-Aug-19 12:00pm GMT
finance.yahoo.com - August 20 at 10:42 AM
Is Matinas BioPharma Holdings (NYSEMKT:MTNB) Using Debt Sensibly?Is Matinas BioPharma Holdings (NYSEMKT:MTNB) Using Debt Sensibly?
finance.yahoo.com - August 14 at 3:34 PM
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q2 2019 Results - Earnings Call TranscriptMatinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 3:36 PM
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Tops Revenue EstimatesMatinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 13 at 3:36 PM
Matinas Biopharma Holdings EPS beats by $0.01, beats on revenueMatinas Biopharma Holdings EPS beats by $0.01, beats on revenue
seekingalpha.com - August 13 at 8:11 AM
Matinas Bio beats Q2 consensusMatinas Bio beats Q2 consensus
seekingalpha.com - August 13 at 8:11 AM
Matinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate UpdateMatinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - August 13 at 8:11 AM
Will Matinas Biopharma Holdings, Inc. (MTNB) Report Negative Earnings Next Week? What You Should KnowWill Matinas Biopharma Holdings, Inc. (MTNB) Report Negative Earnings Next Week? What You Should Know
finance.yahoo.com - August 6 at 12:39 PM
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2019 Operational and Financial Results on August 13, 2019Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2019 Operational and Financial Results on August 13, 2019
finance.yahoo.com - July 30 at 8:42 AM
Matinas Bio up 12% premarket on accelerated review status in U.S. for MAT2203Matinas Bio up 12% premarket on accelerated review status in U.S. for MAT2203
seekingalpha.com - July 25 at 9:42 AM
Matinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal MeningitisMatinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis
finance.yahoo.com - July 25 at 9:42 AM
What Kind Of Investor Owns Most Of Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB)?What Kind Of Investor Owns Most Of Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB)?
finance.yahoo.com - July 9 at 3:27 PM
Assessing An Investment In Matinas BioPharmaAssessing An Investment In Matinas BioPharma
seekingalpha.com - June 25 at 3:28 PM
Matinas BioPharma to Present at the 9th Annual LD Micro InvitationalMatinas BioPharma to Present at the 9th Annual LD Micro Invitational
finance.yahoo.com - June 3 at 8:14 AM
Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBioMatinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio
finance.yahoo.com - May 28 at 8:15 AM
Have Insiders Been Buying Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Shares?Have Insiders Been Buying Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB) Shares?
finance.yahoo.com - May 22 at 3:28 PM
Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019
finance.yahoo.com - May 21 at 3:27 PM
ViiV Healthcare to evaluate Matinas Bios LNC platformViiV Healthcare to evaluate Matinas Bio's LNC platform
seekingalpha.com - May 15 at 3:27 PM
Edited Transcript of MTNB earnings conference call or presentation 14-May-19 12:30pm GMTEdited Transcript of MTNB earnings conference call or presentation 14-May-19 12:30pm GMT
finance.yahoo.com - May 15 at 8:26 AM
Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug CandidatesMatinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates
finance.yahoo.com - May 15 at 8:26 AM
Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1, 2019 Results - Earnings Call TranscriptMatinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1, 2019 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 3:31 PM
Matinas BioPharma Provides Corporate Update and Reports First Quarter 2019 Financial ResultsMatinas BioPharma Provides Corporate Update and Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 14 at 8:36 AM
Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational andMatinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and
www.nasdaq.com - May 8 at 3:26 PM
Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019
finance.yahoo.com - May 8 at 3:26 PM
Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019
finance.yahoo.com - May 2 at 3:25 PM
Matinas BioPharma Selected to Present at the BioNJ Ninth Annual BioPartnering ConferenceMatinas BioPharma Selected to Present at the BioNJ Ninth Annual BioPartnering Conference
finance.yahoo.com - May 1 at 3:25 PM
Matinas BioPharma Holdings IncMatinas BioPharma Holdings Inc
www.bloomberg.com - April 4 at 3:23 PM
Edited Transcript of MTNB earnings conference call or presentation 2-Apr-19 12:00pm GMTEdited Transcript of MTNB earnings conference call or presentation 2-Apr-19 12:00pm GMT
finance.yahoo.com - April 2 at 8:24 PM
Matinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019Matinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019
finance.yahoo.com - March 26 at 8:23 AM
Matinas Biopharma Holdings, Inc.Matinas Biopharma Holdings, Inc.
www.nasdaq.com - March 20 at 10:56 PM
Matinas BioPharma to Present at the 31st Annual ROTH ConferenceMatinas BioPharma to Present at the 31st Annual ROTH Conference
finance.yahoo.com - March 18 at 3:20 PM
Form 8-K Matinas BioPharma Holdin For: Mar 15 - StreetInsider.comForm 8-K Matinas BioPharma Holdin For: Mar 15 - StreetInsider.com
www.streetinsider.com - March 17 at 7:01 PM
Matinas Bio prices stock offering at $1.10; shares down 6% premarketMatinas Bio prices stock offering at $1.10; shares down 6% premarket
seekingalpha.com - March 15 at 3:19 PM
Matinas BioPharma Announces Pricing of Public Offering of Common StockMatinas BioPharma Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 15 at 3:19 PM
Matinas BioPharma -11.7% on secondary offeringMatinas BioPharma -11.7% on secondary offering
seekingalpha.com - March 14 at 7:22 PM
Matinas BioPharma Announces Proposed Public Offering of Common StockMatinas BioPharma Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 14 at 7:22 PM
Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer - GlobeNewswireProminent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer - GlobeNewswire
globenewswire.com - February 25 at 8:31 AM
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel